Trial reportRespiratory research2016
Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study.
Trial report in Respiratory research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Application of type 2 inflammation-related biomarkers in risk prediction models for acute exacerbations in adult asthma: a systematic review.Frontiers in medicine · 2026Pooled it
- StoppingThe European respiratory journal · 2022Trial
- Clinical, functional and inflammatory evaluation in asthmatic patients after a simple short-term educational program: a randomized trial.Scientific reports · 2021Trial
- Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort.The Journal of allergy and clinical immunology · 2020Trial
- Development and initial validation of the Asthma Severity Scoring System (ASSESS).The Journal of allergy and clinical immunology · 2020Trial
- Next Decade Research in Asthma: Broad Omics-Based Exploration Versus Targeted Airway Epithelium Studies.Journal of clinical medicine · 2025Review
- Asthma Phenotypes and Biomarkers.Respiratory care · 2025Review
- Longitudinal hierarchical Bayesian models of covariate effects on airway and alveolar nitric oxide.Scientific reports · 2023Article
- Real-World Evidence on the Diagnostic and Clinical Characteristics of Asthma in Japanese Patients with COPD: The ACO Japan Cohort Study.International journal of chronic obstructive pulmonary disease · 2023Observational
- Type 2 or Non-Type 2 Asthma Exacerbations? That Is the Question.American journal of respiratory and critical care medicine · 2022Article
- Poor Asthma Control in Schoolchildren May Lead to Lower Lung Function Trajectory from Childhood to Early Adulthood: A Japanese Cohort Study.Journal of asthma and allergy · 2022Article
- Relationship between longitudinal changes in type-2 inflammation, immunoglobulin E sensitization, and clinical outcomes in young asthmatics.Clinical and translational allergy · 2021Article
- Variability ofThe World Allergy Organization journal · 2021Article
- Spirometric Response to Bronchodilator and Eucapnic Voluntary Hyperpnea in Adults With Asthma.Respiratory care · 2021Article
- Asthma diagnosis: into the fourth dimension.Thorax · 2021Review
- Type 2-high asthma is associated with a specific indoor mycobiome and microbiome.The Journal of allergy and clinical immunology · 2021Article
- Persistence of Eosinophilic Asthma Endotype and Clinical Outcomes: A Real-World Observational Study.Journal of asthma and allergy · 2021Article
- Innate Lymphoid Cells in Airway Inflammation.Advances in experimental medicine and biology · 2021Article
- Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations.The journal of allergy and clinical immunology. In practice · 2020Article
- Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 5 countries.
Funding
Abstract
backgroundAsthma is a biologically heterogeneous disease and development of novel therapeutics requires understanding of pathophysiologic phenotypes. There is uncertainty regarding the stability of clinical characteristics and biomarkers in asthma over time. This report presents the longitudinal stability over 12 months of clinical characteristics and clinically accessible biomarkers from ADEPT.
methodsMild, moderate, and severe asthma subjects were assessed at 5 visits over 12 months. Assessments included patient questionnaires, spirometry, bronchodilator reversibility, fractional exhaled nitric oxide (FENO), and biomarkers measured in induced sputum.
resultsMild (n = 52), moderate (n = 55), and severe (n = 51) asthma cohorts were enrolled from North America and Western Europe. For all clinical characteristics and biomarkers, group mean data showed no significant change from visit to visit. However, individual data showed considerable variability. FEV1/FVC ratio showed excellent reproducibility while pre-bronchodilator FEV1 and FVC were only moderately reproducible. Of note bronchodilator FEV1 reversibility showed low reproducibility, with the nonreversible phenotype much more reproducible than the reversible phenotype. The 7-item asthma control questionnaire (ACQ7) demonstrated moderate reproducibility for the combined asthma cohorts, but the uncontrolled asthma phenotype (ACQ7 > 1.5) was inconstant in mild and moderate asthma but stable in severe asthma. FENO demonstrated good reproducibility, with the FENO-low phenotype (FENO < 35 ppb) more stable than the FENO-high phenotype (FENO ≥ 35 ppb). Induced sputum inflammatory phenotypes showed marked variability across the 3 sputum samples taken over 6 months.
conclusionsThe ADEPT cohort showed group stability, individual stability in some parameters e.g. low FEV1/FVC ratio, and low FENO, but marked individual variability in other clinical characteristics and biomarkers e.g. type-2 biomarkers over 12 months. This variability is possibly related to seasonal variations in climate and allergen exposure, medication changes and acute exacerbations. The implications for patient selection strategies based on clinical biomarkers may be considerable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.